ESMO Breast 2021 | Treating CNS metastases in HER2+ breast cancer

Thomas Bachelot, MD, PhD, Centre Léon Bérard, Lyon, France, talks on whether treatment of central nervous system (CNS) metastases in HER2+ breast cancer requires a different systemic approach. Dr Bachelot reports that most treatments used for metastatic breast cancer are equally active on brain metastases and systemic disease. Dr Bachelot also comments on the role of novel drug combinations for the treatment of patients with brain cancer and active brain metastases, highlighting the benefits of tucatinib, trastuzumab and capecitabine in combination. This interview took place at the virtual European Society for Medical Oncology (ESMO) Breast Cancer Congress 2021.